Hepatic arterial infusion with nanoliposomal irinotecan leads to significant regression of tumor size of colorectal liver metastases in a CC531 rat model

Long-term therapy for unresectable colorectal liver metastases remains challenging. Intraarterial treatments aim to avoid systemic adverse effects of chemotherapy. Nanoliposomal cytotoxic drugs manage to increase the drug concentration within the tumor while reducing toxicity in healthy tissue.  In...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & experimental metastasis 2023-06, Vol.40 (3), p.235-242
Main Authors: Kauffels, Anne, Nowack, Hannah, Bohnenberger, Hanibal, Spitzner, Melanie, Sprenger, Thilo, Ghadimi, Michael, Sperling, Jens
Format: Article
Language:English
Subjects:
Adenocarcinoma
Animals
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Apoptosis
Biomedical and Life Sciences
Biomedicine
Cancer Research
Caspase-3
Chemotherapy
Colonic Neoplasms - pathology
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Cytotoxicity
Embolization
Fluorouracil
Hematology
Hepatic Artery
Infusions, Intra-Arterial
Irinotecan
Liver
Liver Neoplasms - secondary
Metastases
Metastasis
Oncology
Rats
Research Paper
Sodium chloride
Surgical Oncology
Toxicity
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Long-term therapy for unresectable colorectal liver metastases remains challenging. Intraarterial treatments aim to avoid systemic adverse effects of chemotherapy. Nanoliposomal cytotoxic drugs manage to increase the drug concentration within the tumor while reducing toxicity in healthy tissue.  In this study we analyzed the effect of hepatic arterial infusion (HAI) with nanoliposomal irinotecan with or without the combination of embolization particles in a rat model for colorectal liver metastases. For the study 32 WAG/Rij rats received subcapsular tumor implantation with CC531 rat colonic adenocarcinoma cells. After ten days tumor size was assessed via ultrasound and animals underwent HAI. One group served as control receiving NaCl 0.9 % (Sham), the three treatment groups received either nanoliposomal irinotecan (HAI nal iri), Embocept® S (HAI Embo) or Embocept® S and nanoliposomal irinotecan (HAI Embo+nal iri). Three days after treatment animals were sacrificed after assessment of tumor size. As a result all treatment groups showed a significant reduction in tumor growth compared to Sham (p
ISSN:0262-0898
1573-7276
DOI:10.1007/s10585-023-10209-7